Investing Ideas
/
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Stocks with a return on equity of over 30% and a debt to equity ratio below 1.

7 companies

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
MRK Merck	US$87.68	3.9%	-32.2%	US$216.5b	US$114.05	PE13x	E7.6%	3.7%
WAT Waters	US$380.81	0.4%	15.2%	US$22.4b	US$398.96	PE35.4x	E8.8%	n/a
MEDP Medpace Holdings	US$344.85	0.7%	-12.4%	US$10.5b	US$342.93	PE26x	E9.5%	n/a
PTGX Protagonist Therapeutics	US$38.49	-0.5%	39.0%	US$2.3b	US$58.40	PE13.4x	E-7.2%	n/a
AGIO Agios Pharmaceuticals	US$33.75	1.4%	13.3%	US$1.9b	US$55.14	PE2.9x	E-13.6%	n/a
MDXG MiMedx Group	US$7.85	-5.2%	-4.0%	US$1.2b	US$13.40	PE14.5x	E-1.9%	n/a
SCNI Scinai Immunotherapeutics	US$3.38	4.2%	-32.5%	US$2.9m	n/a	PE0.6x	n/a	n/a

Page 1 of 1